CRISPR-Cas technology is presented as the driver of genetic manipulation and genome editing advances in microalgae, especially in Chlamydomonas reinhardtii.
First-pass extracted concept
CRISPR-Cas technology
Candidate: concept label2 source documents8 linked claims
Live refresh every 5sNext refresh in 5s
Aliases
CRISPR/Cas
Extracted Explainers
What the tool is doing
What problem it solves
It helps overcome prior barriers to engineering microalgae as sustainable biofactories by enabling targeted genome manipulation.
The abstract frames CRISPR/Cas as addressing limitations of conventional genome editing methods that were non-specific, labour-intensive, and time-consuming.
What it does not solve
The abstract states that key technical challenges remain and that current CRISPR-Cas methodologies still require further optimization.
The abstract states that important challenges remain, especially in vivo packaging and delivery efficiency, toxicity, and genomic off-target effects.
Evidence Snippets
Supporting Sources
Linked Claims
Animal models including mice, Drosophila, and zebrafish have benefited from CRISPR for uncovering protein function through reverse genetics strategies such as knock-in, knockout, CRISPRi, and indel mutation.
Quoted textsource-backed
Animal models, including mice, Drosophila, zebrafish, etc., have substantially benefited from CRISPR in uncovering protein function through reverse genetics approaches, including knock-in, knockout, CRISPRi, and indel mutation strategies.
CRISPR/Cas has major applications beyond genome editing in proteomics, functional genomics, and molecular therapy.
Quoted textsource-backed
Beyond its original role in genome editing, CRISPR continues to play a major role in the field of proteomics, functional genomics, and molecular therapy.
CRISPR-Cas technologies in microalgae have impacts on genetic studies, metabolic engineering, and industrial applications.
Quoted textsource-backed
This review provides an overview of the convergence of CRISPR-Cas technologies in microalgae research, highlighting their impact on genetic studies, metabolic engineering, and industrial applications.
CRISPR gene therapy has seen successes in sickle cell disease, hypercholesterolemia, and cancer immunotherapy.
Quoted textsource-backed
On the clinical front, CRISPR gene therapy has also seen successes, including applications in sickle cell disease, hypercholesterolemia, and cancer immunotherapy.
CRISPR/Cas technology is presented as a significant breakthrough relative to conventional genome editing methods described as non-specific, labour-intensive, and time-consuming.
Quoted textsource-backed
Conventional methods available for genome editing have proven non-specific, labour-intensive, and time-consuming. In this context, CRISPR/Cas technology represents a significant breakthrough.
CRISPR-Cas technology is driving a paradigm shift in the genetic manipulation of microalgae.
Quoted textsource-backed
A paradigm shift is currently occurring thanks to the genetic manipulation of microalgae, driven by CRISPR-Cas technology.
Important remaining challenges for CRISPR applications include in vivo packaging and delivery efficiency, toxicity, and genomic off-target effects.
Quoted textsource-backed
However, notable challenges remain, including in vivo packaging and delivery efficiency, toxicity, and genomic off-target effects.
Key challenges remain and further optimization of CRISPR-Cas methodologies is needed to fully realize the genetic potential of Chlamydomonas reinhardtii.
Quoted textsource-backed
Despite this progress, key challenges remain, and further optimization of CRISPR-Cas methodologies is needed to fully unleash the genetic potential of this organism.